Evidence map›Paper›PMID 27600499›Full record

SynthesisScientific reports2016

The efficacy and safety of liraglutide added to metformin in patients with diabetes: a meta-analysis of randomized controlled trials.

Jianqiu Gu, Xin Meng, Yan Guo, Lei Wang, Hongzhi Zheng, Yixuan Liu, Bingshu Wu, Difei Wang

Open access · goldFull text readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 3 pooled it
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 3 syntheses or guidelines pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. The signaling pathways in obesity-related complications.Journal of cell communication and signaling · 2024
    Review
  7. Article
  8. Observational
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Jianqiu GuDepartment of Endocrinology, the First Affiliated Hospital of China Medical University, China.
Xin MengDepartment of Endocrinology, the First Affiliated Hospital of China Medical University, China.
Yan GuoDepartment of Endocrinology, the First Affiliated Hospital of China Medical University, China.
Lei WangDepartment of Geratology, the First Affiliated Hospital of China Medical University, China.
Hongzhi ZhengDepartment of Geratology, the First Affiliated Hospital of China Medical University, China.
Yixuan LiuDepartment of Geratology, the First Affiliated Hospital of China Medical University, China.
Bingshu WuDepartment of Geratology, the First Affiliated Hospital of China Medical University, China.
Difei WangDepartment of Geratology, the First Affiliated Hospital of China Medical University, China.
China Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liraglutide, a glucagon-like peptide (GLP-1) receptor agonist, has showed favorable effects in the glycaemic control and weight reduction in patients with type 2 diabetes mellitus (T2DM). The meta-analysis was to compare the efficacy and safety of liraglutide added to metformin with other treatments in patients with T2DM. A systematic literature search on PubMed, Embase, Web of Science and the Cochrane library databases were performed. Eligible studies were randomized controlled trials (RCTs) of patients with T2DM who received the combination treatment of liraglutide and metformin. Pooled estimates were performed using a fixed-effects model or random-effects model. A total of nine RCTs met the inclusion criteria. Compared with control (placebo, sitagliptin, glimepiride, dulaglutide, insulin glargine, and NPH), liraglutide in combination with metformin resulted in significant reductions in HbA1c, bodyweight, FPG, and PPG, and similar reductions in SBP, and DBP. Moreover, liraglutide combined with metformin did not increase the risk of hypoglycemia, but induced a higher incidence of gastrointestinal disorders. In conclusion, this meta-analysis confirmed the use of liraglutide as add-on to metformin appeared to be effective and safe for patients with T2DM. However, considering the potential limitations in this study, more large-scale, well-conducted RCTs are needed to identify our findings.

Indexed as

Diabetes Mellitus, Type 2Drug Therapy, CombinationGlycated HemoglobinHumansHypoglycemic AgentsLiraglutideMetforminRandomized Controlled Trials as TopicGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic AgentsLiraglutideMetformin

Identifiers

PMID27600499
PMCPMC5013324
OpenAlexW2509428713

What Socratic holds

Textfull text, public
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.